Abstract
The characteristics of lentiviral vectors (stable integration in non-dividing and dividing cells, long-term expression of the transgene, absence of immune response) make them ideal gene transfer vehicula for future gene therapy. However, the most potent lentiviral vectors are derived from highly pathogenic human viruses, such as HIV. We describe how the field has engineered lentivectors with increasing biosafety both for the lab worker and for the patient. The risk associated with state-of-the-art lentivectors is therefore minimal, although a psychological barrier to use these vectors in the clinic may still have to be overcome. Due to their increased performance, care should be taken to avoid accidental transduction of the lab worker with potential hazardous genes. The precautions which have to be taken are described in detail.
Keywords: Lentiviral Vectors, transgene, psychological barrier, immune response
Current Gene Therapy
Title: Biosafety of Lentiviral Vectors
Volume: 3 Issue: 6
Author(s): Zeger Debyser
Affiliation:
Keywords: Lentiviral Vectors, transgene, psychological barrier, immune response
Abstract: The characteristics of lentiviral vectors (stable integration in non-dividing and dividing cells, long-term expression of the transgene, absence of immune response) make them ideal gene transfer vehicula for future gene therapy. However, the most potent lentiviral vectors are derived from highly pathogenic human viruses, such as HIV. We describe how the field has engineered lentivectors with increasing biosafety both for the lab worker and for the patient. The risk associated with state-of-the-art lentivectors is therefore minimal, although a psychological barrier to use these vectors in the clinic may still have to be overcome. Due to their increased performance, care should be taken to avoid accidental transduction of the lab worker with potential hazardous genes. The precautions which have to be taken are described in detail.
Export Options
About this article
Cite this article as:
Debyser Zeger, Biosafety of Lentiviral Vectors, Current Gene Therapy 2003; 3 (6) . https://dx.doi.org/10.2174/1566523034578177
DOI https://dx.doi.org/10.2174/1566523034578177 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family
Current Drug Therapy Drosophila melanogaster in the Study of Human Neurodegeneration
CNS & Neurological Disorders - Drug Targets Inhibition of Intercellular Communication between Prostate Cancer Cells by A Specific Anti-STEAP-1 Single Chain Antibody
Anti-Cancer Agents in Medicinal Chemistry The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets SRLVs: A Genetic Continuum of Lentiviral Species in Sheep and Goats with Cumulative Evidence of Cross Species Transmission
Current HIV Research Gene Silencing in the Development of Personalized Cancer Treatment: The Targets, the Agents and the Delivery Systems
Current Gene Therapy T Lymphocytes as Targets of Gene Transfer with Moloney-Type Retroviral Vectors
Current Gene Therapy Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase
Recent Patents on Anti-Cancer Drug Discovery Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy
Current Topics in Medicinal Chemistry Pharmacological Interventions for the Prevention and Treatment of Kidney Injury Induced by Radiotherapy: Molecular Mechanisms and Clinical Perspectives
Current Molecular Pharmacology Chitosan Derivatives with Antimicrobial, Antitumour and Antioxidant Activities - a Review
Current Pharmaceutical Design Anti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs)
Current Medicinal Chemistry Novel Adjunctive Therapies for the Treatment of Tuberculosis
Current Molecular Medicine Unraveling Potential Candidate Targets Associated with Expression of p16<sup>INK4a</sup> or p16 Truncated Fragment by Comparative Proteomics Analysis
Current Proteomics Molecular Basis for Invertebrate Innate Immune Recognition of (1→3)-β- D-Glucan as A Pathogen-Associated Molecular Pattern
Current Pharmaceutical Design MicroRNA Polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility
Current Pharmacogenomics and Personalized Medicine First-in-human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?
Current Gene Therapy Sulfonamides and Sulfonylated Derivatives as Anticancer Agents
Current Cancer Drug Targets Eicosanoids in Prevention and Management of Diseases
Current Molecular Medicine